


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED**

### **領航醫藥及生物科技有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

## **DELAY IN DESPATCH OF CIRCULAR RELATING TO AMENDMENT TO THE TERMS AND CONDITIONS OF THE CONVERTIBLE BONDS**

Reference is made to the announcement (the “**Announcement**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 12 May 2021 in relation to the Second Deed of Amendment, the Second Deed of Waiver and the transactions contemplated thereunder. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless defined otherwise.

As set out in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of the Second Deed of Amendment, the Second Deed of Waiver and the transactions contemplated thereunder; and (ii) a notice convening the SGM will be despatched to the Shareholders on or before 3 June 2021.

As additional time is required to finalise certain information to be included in the Circular, the Circular is expected to be despatched to the Shareholders on or before 3 July 2021.

By order of the board of  
**Innovative Pharmaceutical Biotech Limited**  
**Tang Rong**  
*Executive Director*

Hong Kong, 3 June 2021

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).*